Clinical Trials · NCT06716424
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 4
- Recruitment status
- Active Not Recruiting
- Sponsor
- Sanofi
- Enrollment
- 105
- Start date
- Jan 2025
- Locations
- 10 sites, India
- Primary endpoint
- Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)